Janssen expands research collaboration with Jubilant Biosys

Janssen has announced an expansion of its existing drug discovery alliance with Jubilant Biosys in order to encompass a number of new fields of study.

Building on Jubilant's diversified skill sets in various therapeutic areas, the companies will be aiming to discover novel chemical entities in multiple disease fields. The alliance was originally formed in 2011 with the aim of delivering preclinical candidates to Janssen.

Most of the new research will be undertaken at Jubilant Biosys' site in India, with some parts carried out at the Jubilant Discovery Center in the US.

In addition to research funding, Jubilant will also receive milestones and royalties should Janssen successfully progress the assets into clinical development and commercialisation.

Dr Subir Basak, president of global drug discovery services at Jubilant Biosys, said: "Over the past several years, we have been strengthening our disease franchises from a scientific perspective, and this collaboration serves as a validation of those efforts."

Last month, Janssen expanded its research capabilities further with the establishment of a new global public health division, which will focus on the development of medicines to meet unmet healthcare needs worldwide.